Multiple Myeloma Bispecifics Vie For Leadership Based On Safety, Combinability

Janssen Has First Combo Data, With Its Own Darzalex

 
• By Mandy Jackson

Updates at ASH for bispecifics targeting BCMA, GPRC5D and FcRH5 from Regeneron, Janssen, Pfizer, Roche, AbbVie and Harpoon show monotherapy efficacy, initial combination data and potential safety differentiation.

Galloping jockeys and race horse toys competing for position
T-cell-recruiting bispecific antibodies are jockeying for position in multiple myeloma • Source: Alamy

More from Clinical Trials

More from R&D